NASDAQ$HLVX
HilleVax Inc · Q1 2023 earnings
Q1 2023 earnings · · Investor relations
Briefing
HilleVax reported financial results for Q1 2023 and highlighted progress on HIL-214 program.
HilleVax reported a net loss of $26.9 million for the first quarter of 2023, with cash and cash equivalents totaling $260.5 million as of March 31, 2023. The company's research and development expenses increased to $23.2 million due to the advancement of the HIL-214 program.
- Completed enrollment of over 3,000 subjects in the NEST-IN1 clinical trial.
- Announced the appointment of Nanette Cocero, Ph.D., MBA, to its Board of Directors.
- Expects topline safety and clinical efficacy data from NEST-IN1 in the first quarter of 2024.
- Cash and cash equivalents totaled $260.5 million as of March 31, 2023.
Headline financials
Revenue & EPS history
HilleVax · Revenue · Quarterly
$0
Forward guidance
Topline safety and clinical efficacy data from NEST-IN1 is expected in the first quarter of 2024.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 6 quarterly earnings reports
-3.3%
Avg return
Earnings day
-2.3%
Avg return
5 days after
-0.9%
Avg return
30 days after
22%
4 / 18 earnings
Positive
+7.9%
Q4 2024
Best reaction
-16.7%
Q2 2023
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q3 2025 | — | — | — | |
| Q2 2025 | +0.5% | +0.5% | +2.0% | |
| Q1 2025 | -1.0% | -5.6% | -6.7% | |
| Q4 2024 | +7.9% | -10.1% | +17.0% | |
| Q3 2024 | -2.6% | +1.6% | +2.6% | |
| Q2 2024 | -0.6% | +5.7% | +8.2% | |
| Q1 2024 | +2.7% | -3.0% | +0.2% | |
| Q4 2023 | -9.0% | -5.4% | -29.5% | |
| Q3 2023 | +1.5% | — | — | |
| Q2 2023 | -16.7% | — | — | |
| Q1 2023 | -1.2% | — | — | |
| Q4 2022 | -12.1% | — | — | |
| Q3 2022 | -8.2% | — | — | |
| Q3 2021 | -8.2% | — | — | |
| Q2 2021 | -6.5% | — | — | |
| Q2 2022 | -6.5% | — | — | |
| Q1 2022 | +0.0% | — | — | |
| Q1 2021 | +0.0% | — | — | |
| Q4 2021 | +0.0% | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro